CHMP approves ACT’s Xydalba (dalbavancin): http://finance.yahoo.com/news/xydalba-dalbavancin-receives-chmp-positive-211500068.html In the US, the brand name for this approved drug is Dalvance. ACT picked up this asset in the Oct 2014 acquisition of DRTX (#msg-106925472).